Purchase Order 75N91020P00734
Award Date 8/12/20
Potential Completion Date 8/12/25
Potential Value $250K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This firm fixed-price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute (NCI) to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The contract provides for preventive and emergency maintenance of government-owned Illumina instrumentation, including MiSeq, cBOT, Freedom EVO, and NextSeq 500 systems, utilized for genome analysis in support of NCI's cancer research....
- This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH), National Cancer Institute (NCI) to Illumina, Inc. for preventive maintenance and repair services on an Illumina NextSeq 2000 sequencing instrument. The contract has a ceiling value of $234,449.00 and runs for an initial 12-month period with four 12-month option periods through August 2026. There is no set-aside designation. Illumina is the original equipment manufacturer (OEM) and the only...
- This is a firm fixed-price purchase order contract awarded by the National Cancer Institute, a civilian agency within the National Institutes of Health, to Illumina, Inc. to maintain and provide preventive maintenance for an Illumina NextSeq 2000 sequencing system. The contract has a ceiling value of $48,209.00 and a performance period ending on March 19, 2026. Illumina is a manufacturer of genetic sequencing and analysis instruments and reagents, and has a history of providing such products and...
- This is a firm fixed price purchase order awarded by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis equipment. The contract provides for an equipment maintenance agreement on Illumina sequencing systems, such as NextSeq, NovaSeq, MiSeq, and iSeq models, with a ceiling value of $16,198.00 and a performance period ending on December 4, 2025. The contract does...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a firm fixed price purchase order contract to Illumina, Inc. for maintenance services on the agency's Illumina MiSeq and NextSeq gene sequencing instruments. The contract has a potential value of $240,423.72 and covers a 12-month base period from May 13, 2019 to May 12, 2020, with four 12-month option periods. The contract provides for preventive maintenance inspections, replacement parts,...
- This is a firm fixed price purchase order awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Illumina, Inc. for preventative maintenance service on a government-owned Illumina NextSeq 550 DNA sequencing instrument. The contract has a potential value of $189,482.72 and a completion date of March 28, 2024. It does not have any set-aside designation. As a manufacturer of genomic sequencing instruments and reagents, Illumina has...
- This is a firm fixed price purchase order awarded by the National Institutes of Health (NIH) Clinical Center to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The contract is for a 12-month base period with a 1-year option to provide comprehensive maintenance services for an Illumina HiSeq 2500 sequencing instrument used to diagnose inherited immune disorders. The contract has a ceiling value of $96,921.00 and was awarded on a sole source basis, as...
- This is a firm fixed-price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. The objective is to procure a comprehensive maintenance plan that includes parts, labor, and materials for an Illumina HiSeq 2500 DNA sequencing instrument. The contract has a ceiling value of $442,123.75 and a period of performance through December 22, 2020. Illumina is a manufacturer of genomic sequencing...
- This firm fixed-price purchase order contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for maintenance services on a government-owned Illumina NovaSeq 6000 sequencing instrument. The $134,247.36 contract provides annual preventive maintenance, emergency repair, software/firmware updates, replacement parts, and technical support for the sequencing system located at the NCI's Laboratory of Pathology in Bethesda,...
- This is a firm fixed price purchase order contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract is for maintenance on a MiSeq instrument, with a potential value of $12,875.00. Illumina has provided a range of sequencing systems, reagents, and services to support genomics research...